<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479687</url>
  </required_header>
  <id_info>
    <org_study_id>SHO-0106</org_study_id>
    <nct_id>NCT00479687</nct_id>
  </id_info>
  <brief_title>SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo Controlled Trial of SUPARTZ (Sodium Hyaluronate) for the Treatment of Chronic Shoulder Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is to determine the safety and effectiveness of three injections of
      SUPARTZ (sodium hyaluronate) compared with saline (placebo) for the treatment of glenohumeral
      osteoarthritis of the shoulder. The trial contains two phases. In the first phase subjects
      are randomized to either SUPARTZ or placebo treatment. The second phase of the trial is
      open-label so all subjects will receive SUPARTZ injections only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III Multi-center, randomized study to determine the safety and efficacy of injections
      of SUPARTZ for Osteoarthritis of the Shoulder
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in shoulder pain compared to subjects treated with placebo</measure>
    <time_frame>over a 26 week period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristic effects of pain improvement over a period of 26 weeks.</measure>
    <time_frame>over a 26 week period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Osteoarthritis of the Shoulder</condition>
  <arm_group>
    <arm_group_label>Supartz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supartz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphate Buffered Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate Buffered Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SUPARTZ</intervention_name>
    <description>Supartz injection into the glenohumeral joint space.</description>
    <arm_group_label>Supartz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phosphate Buffered Saline</intervention_name>
    <description>Saline injection into the glenohumeral joint space.</description>
    <arm_group_label>Phosphate Buffered Saline</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glenohumeral OA confirmed by radiograph

          -  Limitation of shoulder motion in at least one direction

        Exclusion Criteria:

          -  Full thickness rotator cuff tear or rotator cuff tendonopathy

          -  Frozen shoulder

          -  Female who is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Sledge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northeast Orthopedics - Unlimited Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Birbara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology Study Group</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Shoulder</keyword>
  <keyword>HA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 19, 2016</submitted>
    <returned>October 13, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

